NRXP / NRx Pharmaceuticals, Inc. (NRXP) Q4 2022 Earnings Call Transcript

RADNOR, Pa. , Oct. 5, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharma more_horizontal

NRx Pharma (NRXP) receives FDA clearance to begin clinical development for its lead candidate, NRX-101, to treat chronic pain. more_horizontal

RADNOR, Pa. , Sept. 18, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biophar more_horizontal

RADNOR, Pa. , Sept. 7, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biophar more_horizontal

NRX Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Matthew Duffy - Chief Busine more_horizontal

RADNOR, Pa. , Aug. 7, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a late-stage biopharmaceu more_horizontal

RADNOR, Pa. , June 2, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharma more_horizontal

NRx Pharmaceuticals, Inc. (NRXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank more_horizontal